R Klamroth

Summary

Country: Germany

Publications

  1. ncbi request reprint Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia
    R Klamroth
    Department of Angiology and Clotting disorders, Haemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Haemophilia 15:247-52. 2009
  2. ncbi request reprint Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate(®) P) in patients with haemophilia A
    Robert Klamroth
    Department of Internal Medicine Angiology and Clotting Disorders, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany Electronic address
    Thromb Res 134:S38-42. 2014
  3. ncbi request reprint [Acquired bleeding disorders - diagnostic approach]
    R Klamroth
    Klinik für Innere Medizin, Angiologie und Hämostaseologie Hämophiliezentrum, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249, Berlin, Deutschland
    Internist (Berl) 55:514-20. 2014
  4. ncbi request reprint The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation
    Robert Klamroth
    Department for Internal Medicine, Vivantes Hospital in Friedrichshain, Berlin, Germany
    Vasa 42:32-9. 2013
  5. ncbi request reprint Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy
    Robert Klamroth
    Klinik fur Innere Medizin, Angiologie Haemostaseologie und Pneumologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Vasa 39:243-8. 2010
  6. ncbi request reprint [Haemophilia A and haemophilia B. Are there relevant clinical differences?]
    R Klamroth
    Klinik für Innere Medizin Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin
    Hamostaseologie 30:S26-7. 2010
  7. ncbi request reprint The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study
    R Klamroth
    Vivantes Klinikum in Friedrichhain, Klinik fuer Innere Medizin, Haemophiliezentrum, Berlin, Germany
    Haemophilia 17:412-21. 2011

Detail Information

Publications7

  1. ncbi request reprint Successful angiographic embolization of recurrent elbow and knee joint bleeds in seven patients with severe haemophilia
    R Klamroth
    Department of Angiology and Clotting disorders, Haemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Haemophilia 15:247-52. 2009
    ....
  2. ncbi request reprint Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate(®) P) in patients with haemophilia A
    Robert Klamroth
    Department of Internal Medicine Angiology and Clotting Disorders, Haemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, Germany Electronic address
    Thromb Res 134:S38-42. 2014
    ..Pathogen safety is achieved by careful donor selection and a combination of pasteurization and chromatographic purification steps...
  3. ncbi request reprint [Acquired bleeding disorders - diagnostic approach]
    R Klamroth
    Klinik für Innere Medizin, Angiologie und Hämostaseologie Hämophiliezentrum, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249, Berlin, Deutschland
    Internist (Berl) 55:514-20. 2014
    ..Patients with acquired bleeding disorders are often a diagnostic challenge in internal medicine...
  4. ncbi request reprint The influence of thrombophilic risk factors on vascular access survival in chronic dialysis patients in a retrospective evaluation
    Robert Klamroth
    Department for Internal Medicine, Vivantes Hospital in Friedrichshain, Berlin, Germany
    Vasa 42:32-9. 2013
    ..Thrombophilic risk factors are discussed as one cause for occlusion. The aim of this study was to determine if the presence of thrombophilic factors is associated with a reduced survival rate of vascular dialysis access...
  5. ncbi request reprint Bridging with enoxaparin using a half-therapeutic dose regimen: safety and efficacy
    Robert Klamroth
    Klinik fur Innere Medizin, Angiologie Haemostaseologie und Pneumologie, Vivantes Klinikum im Friedrichshain, Berlin, Germany
    Vasa 39:243-8. 2010
    ..We investigated the efficacy and safety of a standardized bridging therapy with enoxaparin in a half-therapeutic dose in patients with a target INR of 2,0 to 3,0...
  6. ncbi request reprint [Haemophilia A and haemophilia B. Are there relevant clinical differences?]
    R Klamroth
    Klinik für Innere Medizin Angiologie und Hämostaseologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin
    Hamostaseologie 30:S26-7. 2010
    ..In comparison to haemophilia A (HA) the bleeding tendency seemed to be less severe. The aim of this study was to investigate this hypothesis in all patients with HA and HB treated in the haemophilia care center of the Vivantes Klinikum...
  7. ncbi request reprint The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study
    R Klamroth
    Vivantes Klinikum in Friedrichhain, Klinik fuer Innere Medizin, Haemophiliezentrum, Berlin, Germany
    Haemophilia 17:412-21. 2011
    ..Physical, but not mental, HRQOL is diminished in HA patients. Target joints are associated with lower physical HRQOL, although this effect is moderated by age...